Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo Q3 2021 Interim Report Steady progression on our journey to build a broader and stronger Orexo PR Newswire UPPSALA, Sweden , Nov. 3, 2021 /PRNewswire/ -- Q3 2021 highlights Total net revenues of SEK 145.9 m (150.3) Net earnings of ...
Orexo´s Nomination Committee for the Annual General Meeting 2022 PR Newswire UPPSALA, Sweden , Nov. 1, 2021 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percen...
Digital Therapeutic MODIA™ Designed to Improve Medication-Assisted Treatment Experience for Opioid Use Disorder Commentary published in the Journal of Medical Internet Research (JMIR) Mental Health PR Newswire MORRISTOWN, N.J. , Oct. 18, 2021 /PRNewswi...
MODIA™ paper published in the Journal of Medical Internet Research Mental Health PR Newswire UPPSALA, Sweden , Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Inter...
Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the second half of 2022. OX124 is designed to reverse the effect of overdoses caused by the most pow...
Orexo AB (ORXOY): Q2 GAAP EPS of -SEK2.15.Revenue of SEK142.8M (-20.3% Y/Y)Press Release For further details see: Orexo AB reports Q2 results
Orexo Q2 2021 Interim Report PR Newswire UPPSALA, Sweden , July 15, 2021 /PRNewswire/ -- "First commercial DTx contract signed with a large healthcare provider" Summary Total net revenues of SEK 142.8 m (179.1) Net earnings of SEK -73.7 m ...
Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo The digital therapeutics, which help manage problematic alcohol use and depression through a cognitive behavioral therapy-based approach, will be available to ...
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® With more than 300,000 users Sober Grid is the largest global social media network for people in recovery from add...
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital therapeutic can be a valuable addition to clinician supervised medication-assisted treat...
News, Short Squeeze, Breakout and More Instantly...
Orexo: invitation to presentation of the Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET . The same ...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...